Resolving these three limitations would help the clinical application of the examination of tissue-resident CD103+CD8+T cells in HCC or ICC tissues for the prediction of therapeutic efficacy and the understanding of immune regulation mechanism of these two malignancies. This evidence concerns the gene CD8A and hepatocellular carcinoma.